ALECTOR INC (ALEC)
US0144421072 - Common Stock
Alector Announces Results from AL002 INVOKE-2 Phase 2 Trial in Individuals with Early Alzheimer’s Disease and Provides Business Update
SOUTH SAN FRANCISCO, Calif., Nov. 25, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering novel,...
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
Alector Secures Flexible Credit Facility for Up to $50 Million From Hercules Capital
SOUTH SAN FRANCISCO, Calif., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering...
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
Alector Reports Third Quarter 2024 Financial Results and Provides Business Update
Data from INVOKE-2, evaluating TREM2 agonist candidate AL002 in patients with early Alzheimer’s disease (AD), on track for 2024 Participant baseline...
Bullish Two Hundred Day Moving Average Cross - ALEC
Alector to Participate in Upcoming Healthcare Conferences
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., Aug. 29, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering...
Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
Alector Reports Second Quarter 2024 Financial Results and Provides Business Update
Data from INVOKE-2 Phase 2 clinical trial of AL002 in individuals with early Alzheimer’s disease (AD) on track for Q4 2024 Patient baseline...
Alector to Host Mid-Year Earnings Conference Call
Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. PT
Alector to Host Mid-Year Earnings Conference Call
Call Scheduled for Wednesday, August 7, 2024, at 4:30 p.m. ET/1:30 p.m. ...
Alector Presents Baseline Characteristics for INVOKE-2 Phase 2 Clinical Trial of AL002 at the Alzheimer's Association International Conference® 2024 (AAIC®)
--INVOKE-2 is the first global Phase 2 trial evaluating the safety and efficacy of a TREM2 agonist, AL002, in slowing disease progression in individuals...
Commit To Buy Alector At $5, Earn 43.3% Annualized Using Options
Alector to Present Data on Pipeline Focus Areas at the Alzheimer's Association International Conference® (AAIC®) 2024
SOUTH SAN FRANCISCO, Calif., July 23, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering...
Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
Alector to Participate in the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
SOUTH SAN FRANCISCO, Calif., June 20, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering...
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation
Alector to Host Virtual Research and Development Event Highlighting Alector Brain Carrier Blood-Brain Barrier Technology Platform
Leading scientific expert to provide insights into emerging technologies for blood-brain barrier modulation...
Alector to Participate in the Goldman Sachs 45th Annual Global Healthcare Conference
Alector to Participate in Upcoming Healthcare Conferences
Alector to Participate in Upcoming Healthcare Conferences
SOUTH SAN FRANCISCO, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Alector, Inc. (Nasdaq: ALEC), a clinical-stage biotechnology company pioneering...
ALEC Stock Earnings: Alector Beats EPS, Beats Revenue for Q1 2024
ALEC stock results show that Alector beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
ALEC Stock Earnings: Alector Beats EPS, Beats Revenue for Q1 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alector (NASDAQ:ALEC) just reported results for the first quarter of 2024.Alect...
Alector Reports First Quarter 2024 Financial Results and Provides Business Update